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ABSTRACT: CPZEN-45 was developed as an antibiotic against Mycobacterium tuberculosis by the chemical modification of 
caprazamycins. CPZEN-45 has been synthesized in this study by the Cu-catalyzed intramolecular amidation of a complex vinyl 
iodide precursor bearing uridine and sugar moieties with a secondary amide, allowing for the construction of its 1,4-diazepin-2-one 
core. 
CPZEN-45 (1) was developed as an antibiotic for the treat-
ment of tuberculosis (TB),1 which is one of the world’s most 
common infectious diseases (Figure 1).2 Notably, CPZEN-45 
exhibits potent antibacterial activity against several multidrug-
resistant strains of Mycobacterium tuberculosis, including 
extensively multidrug-resistant TB. CPZEN-45 was developed 
from the caprazamycins, which are natural products isolated 
from Streptomyces sp. MK730-62F2. Although caprazamycins 
inhibit the activity of the peptidoglycan biosynthetic enzyme 
MraY,3 CPZEN-45 inhibits WecA, which is an enzyme in-
volved in the biosynthesis of mycolyl arabinogalactan.4 Struc-
turally, CPZEN-45 and caprazamycins are both based on a 
seven-membered ring containing two nitrogen atoms, with 
both compounds bearing identical amino ribose and uridine 
moieties. In contrast to the caprazamycins, CPZEN-45 has an 
α,β-unsaturated amide instead of a fatty-acid side chain. 
 
 
Figure 1. Structures of CPZEN-45 and caprazamycins A and B. 
 
Several liponucleoside antibiotics, including caprazamycins, 
have been reported to show potent biological activities, which 
has prompted many groups to engage in synthetic studies to-
wards these compounds.5 In 2015, we reported the first total 
synthesis of caprazamycin A.6 Furthermore, Shibasaki et al. 
recently reported a convergent total synthesis of caprazamycin 
B.7 As part of our ongoing synthetic studies,6 we recently es-
tablished a stereoselective route for the synthesis of β-
hydroxyamino acid derivatives. It was envisaged that this syn-
thetic method could be applied to the synthesis of CPZEN-45, 
although a new method would be required for the construction 
of the 1,4-diazepin-2-one core. Herein, we report our recent 
work towards the synthesis of CPZEN-45 based on a Cu-
catalyzed intramolecular amidation. 
While the 1,4-diazepin-2-one core could be accessed by the 
formation of a saturated 1,4-diazepan-2-one followed by the 
dehydration of a hydroxyl group, the development of a new 
route providing direct access to this structure would be much 
more favorable. We previously reported the Pt-catalyzed 7-
endo cyclization of alkynyl amides for the synthesis of this 
structure.8 However, substrates bearing a sugar moiety failed 
to provide the desired cyclization products under these condi-
tions, presumably because of the unfavorable chelation of the 
oxygen atoms of the sugar to the metal center.9 With this in 
mind, we focused our efforts on the use of an intramolecular 
amidation10 as an alternative strategy for the synthesis of 
CPZEN-45 (1). According to this strategy, the cyclization of 
vinyl iodide 3 would give the 1,4-diazepin-2-one 2, which 
would be converted to 1 by sequential oxidation and amidation 
reactions (Scheme 1). Although the cyclization of a secondary 
amide with a trisubstituted vinyl halide is rare, we hypothe-
sized that this reaction would be promoted by the addition of a 
diamine ligand.11 In this way, it was envisaged that the ligand 
would coordinate to the copper and prevent it from binding to 
the oxygen atoms of the substrate. The cyclization precursor 3 
could be prepared by the coupling of the β-hydroxyamino acid 
 derivative 4 with fluoride 5 and the α,β-unsaturated aldehyde 6. 
Lastly, the synthesis of compound 7 has been reported previ-
ously starting from an oxazolidinone.6,12 Shibasaki and 
Watanabe’s synthesis7b revealed that the nature of the protect-
ing group on the secondary alcohols of the uridine derivative 
was important for the diastereoselectivity of their isocyanate 
aldol reaction. With this in mind, we planned to improve the 
diastereoselectivity of the synthesis of the oxazolidinone pre-
cursor by changing the protecting group used on aldehyde 7. 
 




We initially investigated the Pd- and Cu-catalyzed intramo-
lecular amidation of compound 813 as a model substrate, under 
a variety of conditions previously reported to be successful for 
secondary amides and lactams (Table 1). Following Mori’s 
procedure,14 the treatment of 8 with DPEphos and Cs2CO3, in 
the presence of a catalytic amount of Pd(OAc)2, in toluene at 
80 to 100 °C, gave the desired 1,4-diazepin-2-one 9, along 
with the des-iodo compound 10 in 31% and 26% yields, re-
spectively (Table 1, entry 1). Although the combination of CuI 
with N,N-dimethyl ethylenediamine15 (DMEDA) was found to 
be ineffective, the use of Cu(MeCN)4PF6 with 1,10-
phenanthroline16 gave 1,4-diazepin-2-one 9 along with a con-
siderable amount of alkyne 11 (Table 1, entries 2 and 3). 
These results indicated that the reduction of the vinyl iodide 
competed with the desired cyclization pathway after the oxida-
tive addition step. Spring and co-workers recently reported the 
development of a Cu-catalyzed amination reaction for the syn-
thesis of N-linked biaryl medium ring systems that involved 
the internal coordination of Cu to a nitrogen atom.17,18 Inspired 
by this work, we investigated the possibility of using the two 
nitrogen atoms in our substrate as an internal ligand to stabi-
lize the intermediate and avoid these undesired side reactions 
(Scheme 2). As reported by Spring, the use of CuI with eth-
ylene glycol in EtOH led to a dramatic improvement in the 
yield of the desired product by suppressing the production of 
the unwanted alkyne 11. However, the reaction gave a mixture 
of 9 and 11 when it was conducted in DMF with ethylene gly-
col (Table 1, entries 4–6). In the absence of ethylene glycol, 
the reaction also gave 9 in 70% yield (Table 1, entry 7). Inter-
estingly, the reaction of vinyl iodide 12, bearing a p-nosyl 
protecting group rather than a methyl group,19 failed complete-
ly (Table 1, entry 8). 
 
Table 1. Pd- or Cu-catalyzed amidation of vinyl iodide 8. 
 
Entry R Conditions 
Yield (%) 
9 10 11 
1 Me Pd(OAc)2, DPEphos, Cs2CO3 
toluene, 80 to 100 °C 
31 26 0 
2 Me CuI, Cs2CO3, DMEDA 
toluene, 40 to 80 °C  
0a 0 0 
3 Me Cu(MeCN)4PF6, 1,10-phen  
Rb2CO3, DMA, 40 to 80 °C 
28 0 31 
4 Me CuI, Cs2CO3, ethylene glycol 
DMF, 40 °C 
32 0 61 
5 Me CuI, Cs2CO3, ethylene glycol 
EtOH, 40 °C 
57 0 0 
6 Me CuI, Cs2CO3 
ethylene glycol, 40 °C 
61 0 0 
7 Me CuI, Cs2CO3, EtOH, 40 °C 70 0 0 
8 pNs CuI, Cs2CO3, 
ethylene glycol, 40 °C 
0b 0 0 
a The starting material was recovered in 67% yield. b No reaction. 













Having successfully established good intramolecular ami-
dation conditions for the construction of 1,4-diazepin-2-ones, 
we turned our attention to the synthesis of CPZEN-45. Our 
synthesis started with the aim of improving the diastereoselec-
tive synthesis of oxazolidinone 15 from aldehyde 7. After 
screening an extensive series of bases, protecting groups for 
the secondary alcohol, and nucleophiles, we found that the 
aldol reaction of the known aldehyde 13, which was prepared 
from uridine in four steps,20 with diethyl 2-
((phenoxycarbonyl)amino)malonate (14) proceeded smoothly 
to give the oxazolidinone 15 as a single isomer (Scheme 3).9 
In addition to the excellent selectivity, it is noteworthy that 
this reaction only required (i) a simple base (i.e., K2CO3) and 
(ii) a stable nucleophile, 14, rather than diethyl isocyanomalo-
nate. The oxazolidinone 15 was converted into the β-hydroxy 
amino acid derivative 17 via the trans-oxazolidinone 16 
through sequential decarboxylation, transesterification21 and 
oxazolidinone ring-opening reactions. Notably, this synthetic 
route was robust enough for a 10-gram scale synthesis. 
The cyclization precursor 22 was prepared by the glycosyla-
tion of the β-hydroxy amino acid derivatives 17 with 18 using 
Ichikawa and Matsuda’s procedure.5m,p The resulting com-
pound 19 was subsequently converted to a secondary amine 
via the formation of an amide using Ghosez’s reagent,22 fol-
lowed by N-methylation and the removal of the p-nosyl group. 
The reductive amination of the secondary amine 20 with α,β-
unsaturated aldehyde 623 using NaBH(OAc)3 and AcOH in the 
presence of 4 Å MS gave the cyclization precursor 21 in 72% 
yield. Notably, the addition of 4 Å MS led to an improvement 
in the yield of this reaction. 
Following on from these model studies, we reacted vinyl io-
dide 21 with CuI (1.0 equiv.) and ethylene glycol in ethanol at 
80 °C.24 However, this reaction only resulted in a low yield of 
the desired cyclized product 23 (24% yield), with a significant 
amount of the starting material 21 being recovered unchanged. 
We also investigated the possibility of using a mixed solvent 
system composed of ethylene glycol and EtOH to increase the 
reaction temperature.25 When this solvent system was used at 
80 °C, the reaction did not reach completion (product 22: 35%, 
starting material 21: 36%). Pleasingly, however, the yield of 
22 increased significantly to 77% when the reaction was con-
ducted at 100 °C, with all of the starting material being con-
sumed. Notably, the use of catalytic quantities of CuI (0.2 
equiv.) and ethylene glycol (0.2 equiv.) at 100 °C only result-
ed in a minor decrease in the yield (63%). 
For the final stage of the synthesis, the selective removal of 
the TBS group, followed by a stepwise oxidation and a con-
densation with 4-n-butylaniline gave protected CPZEN-45 
(24). After an extensive investigation, we established that the 
treatment of 24 with aq. HF followed by BCl3
26 allowed a suc-
cessful removal of the TBS, BOM and acetal protecting 
 groups. Subsequent reduction of the azide with PPh3 complet-
ed our synthesis of CPZEN-45. After HPLC purification,27 the 
spectroscopic (1H and 13C NMR, [α]D) and high-resolution 
mass spectrometry data for our synthetic sample were found to 
be identical to those reported for CPZEN-45 TFA salt.1 
In summary, we have developed a Cu-catalyzed reaction for 
the construction of 1,4-diazepin-2-ones by the intramolecular 
amidation of a vinyl iodide with a secondary amide. The ter-
tiary amine of the substrate was found to be essential for the 
cyclization. This method was also used for the synthesis of 
CPZEN-45 by the Cu-catalyzed intramolecular amidation to a 
complex vinyl iodide bearing uridine and sugar moieties. The 
robust nature of this synthesis means that it could be used to 
prepare other analogues of CPZEN-45 that would be otherwise 
impossible to access from caprazamycins. 
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